Deep Vein Thrombosis (DVT) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Deep Vein Thrombosis Pipeline Drugs Market Overview

Deep venous thrombosis is a blood clot that forms in a vein deep inside a part of the body. It mainly affects the large veins in the lower leg and thigh. Symptoms include changes in skin color (redness), leg pain, leg swelling (edema), and skin that feels warm to the touch. The predisposing factors include age, smoking, inheriting a blood-clotting disorder, injury or surgery, cancer, inflammatory bowel disease, and heart failure. Treatment includes thrombolytics and anticoagulants.

For more insights on Deep Vein Thrombosis pipeline drugs market, download a free report sample

Deep Vein Thrombosis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects.

Key Targets in the Deep Vein Thrombosis Pipeline Drugs Market

The key targets in the DVT pipeline market are Coagulation Factor X, Antithrombin III, Coagulation Factor XI, Myosin 9, and Plasminogen. Coagulation Factor X has the highest number of pipeline products in the Deep Vein Thrombosis pipeline market.

Deep Vein Thrombosis Pipeline Drugs Market, by Target

For more target insights, download a free report sample

Key Types of MoA in the DVT Pipeline Market

The key types of MoA in the DVT pipeline market are Coagulation Factor X Inhibitor, Coagulation Factor XI Inhibitor, Antithrombin III Activator, Antithrombin III Inhibitor, Myosin 9 Inhibitor, and Plasminogen Activator. Coagulation Factor X Inhibitor has the highest number of pipeline products in the Deep Vein Thrombosis pipeline market.

Deep Vein Thrombosis Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key Types of RoA in the DVT Pipeline Market

The key types of RoA in the DVT pipeline market are oral, intravenous, subcutaneous, and intravenous bolus. Oral has the highest share in the Deep Vein Thrombosis pipeline market.

Deep Vein Thrombosis Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Deep Vein Thrombosis Pipeline Drugs Market

The key molecule types in the Deep Vein Thrombosis pipeline drugs market are polysaccharide, small molecule, antisense RNAi oligonucleotide, enzyme, monoclonal antibody, and recombinant enzyme. Polysaccharide has the highest pipeline products.

Deep Vein Thrombosis Pipeline Drugs Market, by Molecule Type

For more molecule type insights, download a free report sample

Key Companies in the DVT Pipeline Market

The key companies in the DVT pipeline market are Anthos Therapeutics Inc, Bio-Synectics Inc, CarboMimetics, China Resources Emde Biological Pharmaceutical Co Ltd, Glycan Therapeutics Inc, Guangzhou Dazhou Biomedical Technology Co Ltd, Kolmar Korea Co Ltd, Laboratorios Farmaceuticos Rovi SA, Marizyme Inc, Protheragen Inc, Suzhou Ribo Life Sciences Co Ltd, and Tianjin Pharmaceuticals Group Co Ltd.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT) (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Deep Vein Thrombosis (DVT) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Deep Vein Thrombosis (DVT) (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Deep Vein Thrombosis (DVT) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Deep Vein Thrombosis (DVT) (Cardiovascular)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Deep Vein Thrombosis (DVT) (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.